Suppr超能文献

青蒿素与三氯生或酮康唑联合用药对恶性疟原虫血液期的体外抗疟原虫相互作用。

Antiplasmodial interactions between artemisinin and triclosan or ketoconazole combinations against blood stages of Plasmodium falciparum in vitro.

作者信息

Mishra Lokesh C, Bhattacharya Amit, Bhasin Virendra K

机构信息

Department of Zoology, University of Delhi, North Campus Delhi University, Delhi 110007, India.

出版信息

Am J Trop Med Hyg. 2007 Mar;76(3):497-501.

Abstract

Emergence of drug-resistant Plasmodium falciparum strains to conventional first-line antimalarial drugs has compelled many countries to reorient their drug policies to adopt artemisinin-based combination therapies (ACTs) for treatment of uncomplicated malaria. This has increased the demand of artemisinin, already a scarce commodity. Synthesis of artemisinin is not yet commercially viable. Extensive use of available ACTs will invariably lead to emergence of resistance to these combinations. Thus, there is need to search for new artemisinin-based synthetic, inexpensive, synergistic combinations to reduce dependence on artemisinin. In vitro cultures of P. falciparum provide an appropriate system for identification of such new combinations. We evaluated interactions of artemisinin with triclosan or ketoconazole against blood stages of P. falciparum by a fixed-ratio isobologram method. Artemisinin shows mild synergistic interaction with triclosan and slight to marked antagonism with ketoconazole in vitro. These antiplasmodial interactions, however, require confirmation using in vivo model systems.

摘要

耐氯喹恶性疟原虫菌株对传统一线抗疟药物的出现,迫使许多国家重新调整其药物政策,采用以青蒿素为基础的联合疗法(ACTs)来治疗非复杂性疟疾。这增加了对青蒿素的需求,而青蒿素本身已是一种稀缺商品。青蒿素的合成在商业上尚不具备可行性。广泛使用现有的ACTs将不可避免地导致对这些联合疗法产生耐药性。因此,有必要寻找新的基于青蒿素的合成、廉价、协同的联合疗法,以减少对青蒿素的依赖。恶性疟原虫的体外培养为鉴定此类新联合疗法提供了一个合适的系统。我们通过固定比例等效线图法评估了青蒿素与三氯生或酮康唑对恶性疟原虫血液阶段的相互作用。青蒿素在体外与三氯生表现出轻度协同相互作用,与酮康唑表现出轻微至明显的拮抗作用。然而,这些抗疟原虫相互作用需要使用体内模型系统进行确认。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验